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ensure that the most fruitful research
questions are addressed and the most
appropriate outcome measures used, thus
maximising the potential for die results to
be relevant and beneficial to research
consumers. Furthermore, it should lead to a
more efficient use of research resources.
We are not Luddites calling for an end to
"blue sky" research, and we do not want to
see research by committee, but where the
research relates directly to patients and their
experience of an illness it is essential that
their opinions are gathered.
Sufficient evidence is available to show
that the involvement of consumers in all
aspects of research benefits both researchers
and consumers and that such endeavours
are achievable." We believe that for wide-
spread adoption of consumer involvement
to occur, pressure will have to be brought to
bear by Journal editors and research
councils.
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Morphine induced allodynia in
child with brain tumour
Signs are more likely to have been due to
underlying medical condition
EDITOR—Heger et al remind readers that
high doses of morphine may have paradoxi-
cal eifects.' We are surprised, however, at the
choice of patient they use to illustrate this
lesson.
The diagnosis of pain in an infam
depends solely on the observation of his or
her belwiour.2 It is particularly difScult to
diagnose pain, let alone characterise it äs
allodynia, in a 9 month old infant with con-
siderable neurological deficit and raised
intracranial pressure. The authors attempt
to justify the diagnosis of allodynia in just
such a patient. Furthermore, high dose mor-
phine is well reported äs a cause of rigidity,
catalepsy, akathisia, and myoclonus, which
must add to the difficulty of interpreting
pain on the basis of observation alone.' Two
inconsistencies in the case history under-
mine the speculative diagnosis.
Firsüy, ihe signs of distress provoked
by routine nursing that were interpreted
äs allodynia induced by morphine-3-
glucuronide were also recorded before mor-
phine was given. Secondly, when the
morphine dose was reduced the patient
received methotrimeprazine, dexametha-
sone, and dypirone, each of which could
have eased the signs of distress. The patient's
distress had resolved within a week with this
new treatment regimen, yet the raised ratio
of plasma morphine-3-glucuronide to mor-
phine, which the authors Interpret äs a cause
of her allodynia, remained high for at least
17 days.
We believe that to diagnose allodynia in
this patient is to ignore the much greater
likelihood that the signs were a consequence
of her underlying medical condition. We
therefore agree with the authors that
"morphine induced hyperalgesia has not
been reported in children so far."
Ivan L Marples specialist registrar in anaesthesia and
pain management
Ivan.Marples@doublecycle.demon.co.uk
Paul Murray consultant in anaesthesia and pain
management
Pain and Palliative Support Services, Royal
Hallamshire Hospital, Sheffield S10 2JF'
1 Heger S, Maiei C, Otter K. Helwig U, Suttorp M. Morphine
induced alJodyma in a child with brain tumour. BMJ
1999;319:627-9. (4 September.)
2 Goldman A. ABC oi palliaüve carc: Special probiems of
children. BMJ 1998;316:49-52.
3 Mercadante S. Dantrolene treatment of opioid-mduced
mvoclonus./ljicsi/i Analg 1995:81:1307-8.
Author's reply
EDITOR—Marples and Murray's comments
illustrate how difficult and controversial pae-
diatric palliative care still is. The comments
show that tteatment guidelines alone are not
sufficient for dealing \vith unexpected
complications in terminally ill children with
cancer. The guidelines need to be expanded
to include a diagnostic work up in patients
who do not respond to morphine treatment.
The case we presented was that of a 21
month old patient with an astrocytoma at
final stage. This patient received palliative
care because the tumour was inoperable. We
do not share Marples and Murray's opinion
that the diagnosis of pain in infants depends
solely on observation of their behaviour.
Pain can be quantified even in newborn
infants by analysis of three broad areas:
behaviour patterns (body movements, facial
expression, crying, spectrographic analysis
of the quality of the crying); neurochemical
secretions (catecholamine, Cortisol, renin,
vasopressin, β endorphin concentrations);
and physiology (heart rate, respiratory rate,
blood gas content, palmar sweating). There-
fore it is not difficult to diagnose pain in a 21
month old terminally ill child, even orie with
impaired neurological function.'
The impact of a diagnostic procedure
has to be weighed against any benefit result-
ing from it, especially in palliative care.
Therefore only qualitative instead of quanti-
tative assessment of pain was performed in
this case. There was no question that the
treatment of choice was morphine, the dose
having to be increased gradually according
to the recommendations of the World
Health Organisation.2
We agree with Marples and Murray that
it is difficult to distinguish berween "simple"
pain and morphine induced pain. When
morphine induced allodynia was suspected
in our patient the dose of morphine was 700
times higher than the initial dose. A rapid
reduction of the dose resolved the Symp-
toms of allodynia. To verify die suspicion
that the allodynia was induced by the
morphine we determined plasma concen-
trations of morphine and its metabolites and
detected a relatively raised morphine-3-
glucuronide to morphine ratio in compari-
son with normal data in children.·" We
regret diät no blood sample was taken at the
peak morphine dose. We are confident,
however, that blood concentrations of
morphine-3-glucuronide would have been
even higher during maximal dosing.
We believe that to dispute the diagnosis
of allodynia in this patient is to continue to
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BMJ readers should know whose words
they read
EDITOR—The influence of competing inter-
ests arising from funding by the pharmaceu-
tical industry is worrying in the controversy
about third generation oral contraceptives.1
At the end of 1998 three major studies with-
out Sponsoring from the industry found a
higher risk of venous thrombosis for third
generation contraceptives, unlike three
sponsored studies.2 To date, of nine studies
without Sponsoring, one study found no dif-
ference and the other eight found relative
risks from 1.5 to 4.0 (summary relative risk
2.4); four sponsored studies found relative
risks between 0.8 and 1.5 (summary relative
risk 1.1) (references available on the BMJs
website, www.bmj.com). The sponsored
study with a relative risk of 1.5 has been
reanalysed several times, yielding lower rela-
tive risks; after this failed to convince,1 a new
reanalysis was sponsored by another com-
pany.J
In 1995 four studies found the same risk.
That evidence was sufficient for public
health action since equally reliable pills were
available. For at least one Company the third
generation pill secured more than half its
revenue. The companies proclaimed that
with almost total certainty everything was
the result of bias and confounding. Even for
a sceptic at the time, that was an unreason-
able position: all four studies were reason-
ably executed and had widistood criticism
from the Committee on Safety of Medicines
and reviewers of leading Journals. Thus, the
companies' position ran the high risk of
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damaging both their product and their
credibility. Their behaviour is reminiscent of
that described by Barbara Tuchman in 1984
in The March ofFoüy.from Troy to Vietnam, in
which rulers become removed from reality
and conünuously act against their own best
interests despite clear warnings.
Since 1995 three multinational compa-
nies have used enormous marketing
resources to sow confusion. An avalanche of
special symposia and paid Supplements
convinced Outsiders that something had to
be wrong with the studies finding the
higher risks. Many general practitioners,
gynaecologists, and family planners were
swayed into accepting methodological
arguments that sounded logical because of
their legitimate concern with good contra-
ception. However, few are really trained in
the intricacies of epidemiological argu-
ments. The companies exerted strong legal
pressure on governments. Irresponsible sci-
entists were accused of having caused a pill
scare by juxtaposing selected figures with-
out showing longer time trends in
unwanted pregnancies. Irrelevant compari-
sons abounded, äs with the risk of thrombo-
sis in pregnancy.
The industry's view on bias and con-
founding was disproved by the World
Health Organisation's scientific committee
of leading epidemiologists who were not
involved in the controversy.' Given the
pervasiveness of the competing interest
caused by industry funding, BMJ readers
should know whose words they read.
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Editor^ reply
Readers might be interested to look at our
website and see further debate over compet-
ing interest and third generation contracep-
tive pills.1 Ledger suggested that the BMJ
should not have carried an editorial written
by O'Brien, who was advising lawyers acting
behalf ofwomen who had developed venous
thrombosis while taking third generation
contraceptive pills. Lidegaard, who has writ-
ten for the BMJ on this subject previously,2
disagreed with O'Brien's Interpretation of
the evidence and argued that Professionals
who were "consultants in legal processes
supporting women suifering venous
thromboembolic disease" would be inclined
to Interpret the evidence one way. Neither
Ledger nor Lidegaard declared competing
interests, but I asked them to do so. Ledger
did not reply, but Lidegaard declared several
links with pharmaceutical companies. I
defended our decision to ask O'Brien to
write the editorial, arguing that disclosure is
a better policy than a ban because people
who are deeply knowledgeable on a subject
and wholly independent are vanishingly
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Science is not a dispassionate activity
EDITOR—The need for transparency in mat-
ters of competing interests, highlighted by
Smith,1 is amply illustrated by the recent
controversy about third generation oral
contraceptives. During this debate consider-
able sums of money have been spent
denigrating well conducted studies with
both clear hypotheses at the outset and
clear analyses, studies which unexpectedly
found that newer pills containing des-
ogestrel and gestodene were associated with
higher risks of venous thrombosis than
older preparations with other pro-
gestogens. Often highly personalised
attacks have been made to discredit the
work of well respected researchers, regula-
tory authorities, and the World Health
Organisation. At the same time studies with
non-validated data, subgroup analyses after
the event, controls of different ages
recruited for another study, and inappropri-
ate statistical adjustments have been pro-
moted äs providing robust evidence of an
absence of risk. The proponents of such
arguments have often been paid consult-
ants of companies manufacturing oral con-
traceptives, or people receiving large
research grants from these companies.
Would such efforts have been made if the
first studies had found differences in favour
of third generation pills rather than against
them?
To this mixture of claim and counter-
claim has been added the smokescreen of
whether particular oral contraceptives have
different risks of myocardial infarction. For
most women this issue is irrelevant. Most
women stop taking the pill before their mid-
30s, well before the age when women
experience myocardial infarction. Further-
more, women at low risk—that is, those who
do not smoke, who do not have hyper-
tension, and who have their blood pressure
measured before taking the pill—are not at
risk of myocardial infarction, regardless of
the preparation used.
Science is not a dispassionate activity.
Money is a powerful motivator, and, äs
O'Brien points out in his editorial,2 the
stakes are high. A desire for fame, an exces-
sive belief in your own work, and jealousy
can also distort personal perspectives. The
truth might never be established to the sat-
isfaction of all parties, and even in the age of
evidence based medicine opinion guides
clinical practice. After much time evaluating
the various arguments (including time äs a
paid consultant to the World Health
Organisation's scientific group on Cardio-
vascular disease and steroid hormone
contraception1), I have concluded, like
O'Brien, that all currently available oral
contraceptives are safe. I have also con-
cluded that the older formulations have a
smaller risk of venous thromboembolism
than newer preparations containing des-
ogestrel or gestodene. For this reason, I
believe diät these older preparations
remain the preferred first choice for most
women.
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Italian paediatric association
has launched code on
competing interests
EDITOR—The BMJs policy of promoting the
declaration of competing interests by
authors is praiseworthy and should concern
more people than the journal's contribu-
tors.1 Transparency should be requested of
lecturers äs well äs organisers of and
delegates to Workshops and congresses.
Bero's editorial shows how things are
changing with publication of the Royal Col-
lege of Paediatrics and Child Health's ,
report.5 This idea is also taking hold in Italy. ,
In 1998 our association, whose main ,
aims are providing continuing medical edu- ,
cation, promoting primary care research,
and protecting children, launched an initia-
tive to develop a code on competing .
interests. This was based on the principles of
the code of the International Pharmaceuti- '
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